MA
ADMA icon

MCF Advisors’s ADMA Biologics ADMA Stock Holding History

MCF Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.15K Sell
905
-377
-29% -$5.95K ﹤0.01% 1005
2025
Q4 		$23.4K Buy
1,282
+825
+181% +$13.9K ﹤0.01% 667
2025
Q3 		$6.7K Buy
+457
New +$7.83K ﹤0.01% 761

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

MCF Advisors's ADMA Position: Q1 2026 in Review

MCF Advisors reduced its ADMA Biologics (ADMA) stake by 29% in Q1 2026, selling an estimated $5.95K and leaving 905 shares worth $8.15K. The position accounts for ﹤0.01% of the portfolio, ranked #1005.

MCF Advisors first reported a position in ADMA in Q3 2025 and has held it in 3 quarters since. The position peaked at $23.4K in Q4 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • MCF Advisors held 905 shares of ADMA Biologics worth $8.15K as of Q1 2026.
  • MCF Advisors sold 377 ADMA Biologics shares in Q1 2026, an estimated $5.95K.
  • ADMA Biologics made up ﹤0.01% of MCF Advisors's portfolio in Q1 2026, its #1005 holding.
  • MCF Advisors first reported a position in ADMA Biologics in Q3 2025 and has held it in 3 quarters since.
  • MCF Advisors's ADMA Biologics position peaked at $23.4K in Q4 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on MCF Advisors's 13F filing for Q1 2026, filed 11 May 2026.